Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Male Sexual Response: Erection & Ejaculation01:17

Male Sexual Response: Erection & Ejaculation

Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional and morphological changes in cultured neurons of rat cerebral cortex induced by long-term application of aluminum.

Biochemical and biophysical research communications·1992
Same author

Augmentation of retinoic acid-induced granulocytic differentiation in HL-60 leukemia cells by serine/threonine protein phosphatase inhibitors.

FEBS letters·1992
Same author

Cytohistologic assessment of antitumor effects of intraperitoneal hyperthermic perfusion with mitomycin C for patients with gastric cancer with peritoneal metastasis.

Cancer·1992
Same author

Stereo architecture of the connective tissue cores of the lingual papillae in the treeshrew (Tupaia glis).

Anatomy and embryology·1992
Same author

Effects of milrinone on lung water content in dogs with acute pulmonary hypertension.

Journal of pharmacological and toxicological methods·1992
Same author

A retrospective study on delirium type.

The Japanese journal of psychiatry and neurology·1992

Related Experiment Video

Updated: Jun 22, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Orgasm is preserved regardless of ejaculatory dysfunction with selective alpha1A-blocker administration.

K Kobayashi1, N Masumori, R Kato

  • 1Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan. kou@sapmed.ac.jp

International Journal of Impotence Research
|June 19, 2009
PubMed
Summary

Selective alpha1A-blocker silodosin caused ejaculatory dysfunction, but orgasm sensation was preserved in healthy males. Most participants were dissatisfied due to the lack of seminal emission, despite mild discomfort.

Related Experiment Videos

Last Updated: Jun 22, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

  • Urology
  • Pharmacology
  • Sexual Medicine

Background:

  • Selective alpha1A-blockers are used to treat lower urinary tract symptoms.
  • Silodosin is a selective alpha1A-blocker known to cause ejaculatory dysfunction.

Purpose of the Study:

  • To evaluate the impact of silodosin-induced ejaculatory dysfunction on the sensation of orgasm.
  • To assess participant satisfaction with orgasm during reduced or absent seminal emission.

Main Methods:

  • A randomized, double-blind, crossover study involving 15 healthy male volunteers.
  • Administration of silodosin or placebo, with assessment of ejaculatory volume and self-reported questionnaire data on orgasm and satisfaction.

Main Results:

  • All participants experienced a complete lack of seminal emission and expulsion while taking silodosin.
  • All participants reported experiencing orgasm despite the absence of seminal emission.
  • 80% of participants reported discomfort during orgasm and dissatisfaction with the lack of seminal emission, though often mild.

Conclusions:

  • Orgasm sensation is preserved even when seminal emission is absent due to silodosin.
  • While orgasm is maintained, the lack of seminal emission leads to significant dissatisfaction among users.